All-trans-retinoic Acid Ameliorates Hepatic Steatosis in Mice by a Novel Transcriptional Cascade
Overview
Authors
Affiliations
Unlabelled: Mice deficient in small heterodimer partner (SHP) are protected from diet-induced hepatic steatosis resulting from increased fatty acid oxidation and decreased lipogenesis. The decreased lipogenesis appears to be a direct consequence of very low expression of peroxisome proliferator-activated receptor gamma 2 (PPAR-γ2), a potent lipogenic transcription factor, in the SHP(-/-) liver. The current study focused on the identification of a SHP-dependent regulatory cascade that controls PPAR-γ2 gene expression, thereby regulating hepatic fat accumulation. Illumina BeadChip array (Illumina, Inc., San Diego, CA) and real-time polymerase chain reaction were used to identify genes responsible for the linkage between SHP and PPAR-γ2 using hepatic RNAs isolated from SHP(-/-) and SHP-overexpressing mice. The initial efforts identify that hairy and enhancer of split 6 (Hes6), a novel transcriptional repressor, is an important mediator of the regulation of PPAR-γ2 transcription by SHP. The Hes6 promoter is specifically activated by the retinoic acid receptor (RAR) in response to its natural agonist ligand, all-trans retinoic acid (atRA), and is repressed by SHP. Hes6 subsequently represses hepatocyte nuclear factor 4 alpha (HNF-4α)-activated PPAR-γ2 gene expression by direct inhibition of HNF-4α transcriptional activity. Furthermore, we provide evidences that atRA treatment or adenovirus-mediated RAR-α overexpression significantly reduced hepatic fat accumulation in obese mouse models, as observed in earlier studies, and the beneficial effect is achieved by the proposed transcriptional cascade.
Conclusions: Our study describes a novel transcriptional regulatory cascade controlling hepatic lipid metabolism that identifies retinoic acid signaling as a new therapeutic approach to nonalcoholic fatty liver diseases.
All-trans retinoic acid induces lipophagy by reducing Rubicon in Hepa1c1c7 cells.
Nguyen A, Masuda M, Mori Y, Adachi Y, Fukuda T, Furuichi A J Lipid Res. 2024; 65(8):100598.
PMID: 39032560 PMC: 11381443. DOI: 10.1016/j.jlr.2024.100598.
Tyczynska M, Hunek G, Szczasny M, Brachet A, Januszewski J, Forma A Int J Mol Sci. 2024; 25(9).
PMID: 38732128 PMC: 11085010. DOI: 10.3390/ijms25094916.
Liu Y, Qin X, Chen T, Chen M, Wu L, He B Front Nutr. 2024; 11:1344924.
PMID: 38549744 PMC: 10973017. DOI: 10.3389/fnut.2024.1344924.
Targeting nuclear receptors for NASH/MASH: From bench to bedside.
Sinha R Liver Res. 2024; 8(1):34-45.
PMID: 38544909 PMC: 7615772. DOI: 10.1016/j.livres.2024.03.002.
Retinoic Acid Signaling in Fatty Liver Disease.
Cassim Bawa F, Zhang Y Liver Res. 2023; 7(3):189-195.
PMID: 37854944 PMC: 10583737. DOI: 10.1016/j.livres.2023.07.002.